ROCKVILLE, MD – Biotech giant MacroGenics sent shockwaves through the financial world today, not by turning a profit, but by meticulously failing to meet the market's worst expectations. The company proudly reported a GAAP EPS of -$1.18, a figure that miraculously “beats” analyst predictions by a full three cents, sending its stock price rocketing in after-hours trading.

“We are incredibly proud of our team’s dedication to losing less money than the experts thought we would,” stated CEO Dr. Evelyn Thorne in a press release that was noticeably devoid of any mention of actual profitability. “This quarter’s results demonstrate our unparalleled ability to manage investor expectations downwards, then exceed those lowered expectations. It’s a delicate dance, and frankly, we’re crushing it.”

Revenue also impressed, hitting $149.5 million, $13.38 million more than the market had braced itself for. Analysts quickly lauded the company’s strategic genius. “It’s a masterclass in financial optics,” remarked market strategist Chad ‘The Bull’ Barrington. “They’re not just losing money; they’re losing it *better* than anyone else. That’s the kind of innovation Wall Street craves.”

Sources close to the company indicate that future guidance will involve an even more aggressive strategy of underperforming less dramatically.